Indian Journal of Nuclear Medicine

INTERESTING IMAGE
Year
: 2021  |  Volume : 36  |  Issue : 1  |  Page : 92--94

Obstructive jaundice: An unusual presentation of neuroendocrine differentiation in prostatic adenocarcinoma


Sampath Santhosh1, Godwin Jeeva1, Ranjan Kumar Mohapatra2,  
1 Division of PET/CT, Gemini Scans, Chennai, Tamil Nadu, India
2 Institute of Oncology, SRM Institute of Medical Sciences, Chennai, Tamil Nadu, India

Correspondence Address:
Dr. Sampath Santhosh
Division of PET/CT, Gemini Scans, Vadapalani, Chennai - 600 026, Tamil Nadu
India

Abstract

An elderly male on androgen deprivation therapy for prostatic adenocarcinoma presented with obstructive jaundice. Since biopsy from the head of the pancreas showed neuroendocrine carcinoma (NEC), he was diagnosed with second primary pancreatic NEC. Ga-68 DOTANOC positron emission tomography/computed tomography (PET/CT) done subsequently showed enlarged mildly DOTANOC-avid retroperitoneal nodes infiltrating the pancreas. These nodes were found to be progression of prostate-specific membrane antigen (PSMA) nonavid retroperitoneal nodes visualized in his Ga-68 PSMA PET/CT performed at another institution before 4 months, when there was no lesion in the pancreas. This observation revised the diagnosis from second primary pancreatic NEC to progression of neuroendocrine differentiation in preexisting prostatic adenocarcinoma.



How to cite this article:
Santhosh S, Jeeva G, Mohapatra RK. Obstructive jaundice: An unusual presentation of neuroendocrine differentiation in prostatic adenocarcinoma.Indian J Nucl Med 2021;36:92-94


How to cite this URL:
Santhosh S, Jeeva G, Mohapatra RK. Obstructive jaundice: An unusual presentation of neuroendocrine differentiation in prostatic adenocarcinoma. Indian J Nucl Med [serial online] 2021 [cited 2023 Feb 9 ];36:92-94
Available from: https://www.ijnm.in/text.asp?2021/36/1/92/310777


Full Text



A 68-year-old male presented with obstructive jaundice having total and direct serum bilirubin of 9.5 mg/dl and 5.3 mg/dl, respectively. He had been on treatment with androgen deprivation therapy (ADT) over 2 years for prostatic adenocarcinoma. His magnetic resonance imaging suggested a lesion involving head and uncinate process of the pancreas [arrows in [Figure 1]a, [Figure 1]b and [Figure 1]d, resulting in cutoff of common bile duct (CBD) and pancreatic duct [arrows in [Figure 1]c. Endoscopic ultrasound-guided biopsy from the head of the pancreas revealed neuroendocrine carcinoma (NEC), leading to a working diagnosis of pancreatic NEC as second primary. He was then treated with CBD stenting and was referred for DOTANOC positron emission tomography/computed tomography (PET/CT) [Figure 2]a to assess the pancreatic NEC. It showed low-grade DOTANOC uptake (maximum standardized uptake value [SUVmax] 3.2) in enlarged retroperitoneal nodes [arrow head in [Figure 2]b with infiltration into the head and body of the pancreas [arrow head in [Figure 2]c. The pancreas showed diffuse enlargement and low-grade DOTANOC uptake suggesting pancreatitis [Figure 2]c, which has resulted in CBD cutoff and obstructive jaundice. An intensely DOTANOC-avid (SUVmax 7.5) left adrenal metastasis [arrow in [Figure 2]d was also visualized. Apart from these findings, DOTANOC nonavid enlarged left renal hilar nodes [arrow in [Figure 2]b, right adrenal metastasis [arrow head in [Figure 2]d, few mesenteric nodes, and pleural effusion were also visualized. No abnormality was detected in the prostate.{Figure 1}{Figure 2}

Four months back, the patient had undergone Ga-68 prostate-specific membrane antigen (PSMA)-PET/CT [PSMA-2, [Figure 3]a at another institution for raising serum prostate-specific antigen (16.1 ng/ml). It had showed disease progression by means of appearance of PSMA-avid perinephric deposits, paraesophageal, left renal hilar [arrow in [Figure 3]b, and retrocaval lymph nodes and increase in the size of PSMA-avid right adrenal metastases [arrow head in [Figure 3]d compared to another Ga-68 PSMA-PET/CT (PSMA-1, images not shown) 1 year ago. Few other new PSMA nonexpressing retroperitoneal nodes were also noted in the para-aortic, aortocaval regions [arrow head in [Figure 3]b and [Figure 3]c. On comparative analysis, it was noted that the newly detected retroperitoneal nodes in the PSMA-2 PET/CT had increased in size over the subsequent months causing pancreatic infiltration and obstructive jaundice. Since these lesions were NEC in nature, DOTANOC PET/CT showed only low-grade uptake in these lesions. Furthermore, all the PSMA-avid lesions in PSMA-2 PET/CT increased in size with no DOTANOC uptake. DOTANOC avidity in the newly detected left adrenal metastasis suggested well-differentiated neuroendocrine tumor. Based on these findings, the diagnosis was made in favor of neuroendocrine differentiation (NED) of prostatic adenocarcinoma with disease progression.{Figure 3}

Neuroendocrine cells are scattered in all zones of prostatic glands comprising <1% of prostatic glandular epithelium. Prostatic adenocarcinomas may have NED commonly presenting post-ADT as an androgen receptor inhibition resistance phenomenon.[1] Ga-68-DOTANOC PET/CT has been playing a significant role in diagnosis and management of this challenging condition.[2],[3],[4],[5],[6],[7] NED as the cause of metastatic recurrence diagnosed by Ga-68-DOTANOC in pancreatic adenocarcinoma with negative PSMA scan has been reported.[4] Our case is different in that the patient had significant PSMA-avid lesions throughout the course of his illness, when the latest PSMA-PET/CT showed new PSMA-avid lesions along with non-PSMA-avid retroperitoneal lymphadenopathy.

Had the suspicion of NED been made based on PSMA-negative lymphadenopathy,[8] an early attempt to diagnose NED could have been made with appropriate management decisions which would have possibly prevented or delayed the development of obstructive jaundice in our patient. Furthermore, the findings in Ga-68 DOTANOC PET/CT helped in revising the diagnosis to NED of prostatic adenocarcinoma from pancreatic NEC. The low-grade uptake in DOTANOC PET/CT was consistent with NEC rather than a well-differentiated neuroendocrine neoplasm. Although FDG PET/CT would have shown intense uptake in NEC lesions in our case, we deferred it since a pathological confirmation of NEC was already obtained. The newly detected DOTANOC-avid left adrenal metastasis represented a well-differentiated component of NED in prostatic adenocarcinoma consistent with the heterogeneity of these neoplasms. Our case reaffirms the fact that NED should be suspected when PSMA-negative lesions are visualized during the follow-up of patients with prostate adenocarcinoma, especially in post-ADT metastatic setting.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient (s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initial s will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: A review. Am J Clin Exp Urol 2014;2:273-85.
2Chen S, Cheung SK, Wong KN, Wong KK, Ho CL. 68Ga-DOTATOC and 68Ga-PSMA PET/CT unmasked a case of prostate cancer with neuroendocrine differentiation. Clin Nucl Med 2016;41:959-60.
3Parida GK, Tripathy S, Datta Gupta S, Singhal A, Kumar R, Bal C, et al. Adenocarcinoma prostate with neuroendocrine differentiation: Potential utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT. Clin Nucl Med 2018;43:248-9.
4Usmani S, Ahmed N, Marafi F, Rasheed R, Amanguno HG, Al Kandari F. Molecular imaging in neuroendocrine differentiation of prostate cancer: 68Ga-PSMA versus 68Ga-DOTA NOC PET-CT. Clin Nucl Med 2017;42:410-3.
5Giovacchini G, Giovannini E, Riondato M, Ciarmiello A. Radiopharmaceuticals for the diagnosis and therapy of neuroendocrine differentiated prostate cancer. Curr Radiopharm 2017;10:6-15.
6Assadi M, Pirayesh E, Rekabpour SJ, Zohrabi F, Jafari E, Nabipour I, et al. 177Lu-PSMA and 177Lu-DOTATATE therapy in a patient with metastatic castration-resistant prostate cancer and neuroendocrine differentiation. Clin Nucl Med 2019;44:978-80.
7Acar E, Kaya GÇ. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA positive metastatic large cell neuroendocrine prostate tumor. Clin Nucl Med 2019;44:53-4.
8Chakraborty PS, Tripathi M, Agarwal KK, Kumar R, Vijay MK, Bal C. Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: Negative on 68Ga-PSMA PET/CT. Clin Nucl Med 2015;40:e163-6.